



## DECLARATORY JUDGMENT ACTION FILED BY GSK

*Summary: GSK has today filed a declaratory judgment action seeking a declaration that the US Patent 6,331,415 (the “Cabilly” patent) is invalid, unenforceable and not infringed by Arzerra.*

**Copenhagen, Denmark; October 8, 2009** – Genmab A/S (OMX: GEN) announced today that in connection with Genmab’s collaboration agreement with GSK regarding ofatumumab (Arzerra™) GSK has today filed a declaratory judgment action at the United States District Court for the Southern District of Florida seeking a declaration that U.S. Patent 6,331,415 (the “Cabilly” patent) owned by Genentech, Inc. and City of Hope, is invalid, unenforceable and not infringed by Arzerra. The filing of this action is not expected to affect Genmab’s financial guidelines for 2009.

### About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit [www.genmab.com](http://www.genmab.com).

*This Stock Exchange Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s Annual Report, which is available on [www.genmab.com](http://www.genmab.com). Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.*

Genmab®, the Y-shaped Genmab logo®, HuMax®, HuMax-CD20®, HuMax-EGFr™, HuMax-IL8™, HuMax-TAC™, HuMax-HepC™, HuMax-CD38™, HuMax-CD32b™, HuMax-TF™, HuMax-Her2™, HuMax-VEGF™ and UniBody® are all trademarks of Genmab A/S. Arzerra™ is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations  
T: +45 33 44 77 30; M: +45 25 27 47 13; E: [h.husted@genmab.com](mailto:h.husted@genmab.com)

###